Alpha Tau Medical’s (DRTS) First International Brain Cancer Use Tests The Breadth Of Its Alpha DaRT Platform

Alpha Tau Medical recently reported that its Alpha DaRT technology was used to safely treat a recurrent glioblastoma patient ...
Nasdaq

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

- First-in-kind technology delivers intra-tumoral alpha-emitting radiotherapeutics, reflects strength of clinical data and strong collaboration with Japanese regulators and clinical societies - By ...

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

First glioblastoma patient ever treated with Alpha DaRT® outside of the United States, and the first in Israel - performed at Hadassah ...
Business Wire

HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT

TOKYO--(BUSINESS WIRE)--HekaBio K.K., (Headquarters: Chuo-ku, Tokyo) announces that the innovative solid tumor treatment device ‘Alpha DaRT (Diffusing Alpha Radiation Therapy),’ developed by Alpha Tau ...